| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
HCV-IN-30 targets the HCV NS5A replication complex, a multifunctional protein essential for viral RNA replication and assembly. NS5A is a zinc-binding phosphoprotein that plays a critical role in the HCV life cycle, including viral RNA replication, modulation of host cell signaling, and interferon resistance. By inhibiting the NS5A replication complex, HCV-IN-30 disrupts the formation of the viral replication machinery, thereby blocking viral RNA synthesis. This mechanism of action is distinct from that of direct-acting antivirals targeting viral proteases or polymerases, making NS5A inhibitors an important class of anti-HCV agents.
|
|---|---|
| ln Vitro |
HCV-IN-30 exhibits potent in vitro antiviral activity against HCV replicons. It demonstrates IC50 values of 901 nM and 102 nM against genotypes 1a and 1b replicons, respectively. These values indicate that the compound is significantly more effective against the genotype 1b strain. The compound's activity is assessed in cell-based replicon systems, where it inhibits HCV RNA replication in a dose-dependent manner. Its selectivity for the viral replication complex over host cellular processes makes it a promising candidate for further development as an anti-HCV therapeutic.
|
| ln Vivo |
In vivo activity of HCV-IN-30 has been evaluated in animal models of HCV infection. As an NS5A replication complex inhibitor, the compound is expected to suppress viral load and improve liver pathology in infected animals. However, detailed in vivo data, including efficacy in reducing viral titers and improving survival, are not extensively documented in publicly available sources. The compound's oral bioavailability and pharmacokinetic properties would be critical for its in vivo efficacy. Further studies are needed to fully characterize its therapeutic potential in animal models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for HCV-IN-30 typically measure its binding affinity to the HCV NS5A protein. These assays use surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to determine the dissociation constant (Kd) for the compound-NS5A interaction. Alternatively, fluorescence polarization-based competitive binding assays can be employed using a fluorescently labeled NS5A ligand. The compound's ability to inhibit NS5A's function in RNA replication can be assessed using in vitro RNA-dependent RNA polymerization assays with purified NS5A protein and viral RNA templates.
|
| Cell Assay |
In vitro cellular assays for HCV-IN-30 are conducted using HCV replicon cell lines, such as Huh-7 cells harboring subgenomic or genomic HCV replicons of genotypes 1a and 1b. Cells are treated with varying concentrations of the compound, and HCV RNA replication is quantified by real-time PCR or by measuring the activity of a reporter gene (e.g., luciferase) incorporated into the replicon construct. The half-maximal inhibitory concentration (IC50) is determined from dose-response curves. Cytotoxicity is assessed in parallel using standard cell viability assays (e.g., MTT) to calculate the selectivity index.
|
| Animal Protocol |
In vivo animal experiments with HCV-IN-30 are typically conducted in mouse models of HCV infection, such as humanized liver chimeric mice (e.g., uPA-SCID mice) or transgenic mice expressing HCV proteins. The compound is administered orally or by intraperitoneal injection at various doses. Blood samples are collected at multiple time points to measure plasma compound concentrations and viral load (HCV RNA). Liver tissues are harvested for histopathological analysis and for measuring intrahepatic HCV RNA levels. Pharmacodynamic endpoints include reduction in serum HCV RNA and improvement in liver enzyme levels.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic (PK) data for HCV-IN-30 are limited in publicly available sources. The compound has a molecular weight of 624.77 and a molecular formula of C36H44N6O4. It is typically stored at -20°C and is soluble in DMSO. For in vivo studies, the compound would be formulated in appropriate vehicles for oral or intraperitoneal administration. Its half-life, bioavailability, and tissue distribution would need to be characterized in preclinical studies to support its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for HCV-IN-30 are not extensively published. The compound is intended for research use only and is not approved for human therapeutic use. In preclinical studies, the safety profile appears acceptable at efficacious doses, but full toxicological characterization has not been reported. Standard safety assessments such as cytotoxicity assays in relevant cell lines are typically performed alongside efficacy studies to determine the therapeutic window. The compound should be handled with appropriate laboratory safety precautions. Further toxicity studies are needed to support any potential clinical development.
|
| References | |
| Additional Infomation |
HCV-IN-30 is a research compound used as a potent and selective HCV NS5A replication complex inhibitor. It is a useful tool for studying HCV replication mechanisms and for developing new antiviral strategies. The compound's activity against both genotypes 1a and 1b replicons makes it valuable for cross-genotype efficacy studies. It is available in high purity (95%) for research applications. HCV-IN-30 can be combined with other direct-acting antivirals, such as protease or polymerase inhibitors, to assess synergistic antiviral activity and to study combination therapy approaches for hepatitis C.
|
| Molecular Formula |
C₃₆H₄₄N₆O₄
|
|---|---|
| Molecular Weight |
624.77
|
| Exact Mass |
624.342
|
| CAS # |
1007882-23-6
|
| PubChem CID |
24898407
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
890.2±65.0 °C at 760 mmHg
|
| Flash Point |
492.2±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
5.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
46
|
| Complexity |
962
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)(C)OC(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)OC(C)(C)C
|
| InChi Key |
WPMTYMFNINZZHE-KYJUHHDHSA-N
|
| InChi Code |
InChI=1S/C36H44N6O4/c1-35(2,3)45-33(43)41-19-7-9-29(41)31-37-21-27(39-31)25-15-11-23(12-16-25)24-13-17-26(18-14-24)28-22-38-32(40-28)30-10-8-20-42(30)34(44)46-36(4,5)6/h11-18,21-22,29-30H,7-10,19-20H2,1-6H3,(H,37,39)(H,38,40)/t29-,30-/m0/s1
|
| Chemical Name |
tert-butyl (2S)-2-[5-[4-[4-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
|
| Synonyms |
HCVIN30; HCV IN 30
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~32.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2 mg/mL (3.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL | |
| 5 mM | 0.3201 mL | 1.6006 mL | 3.2012 mL | |
| 10 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
